Advertisement

Annals of Surgical Oncology

, Volume 21, Issue 8, pp 2725–2732 | Cite as

Thyroglobulin Antibodies Could be a Potential Predictive Marker for Papillary Thyroid Carcinoma

  • Ioannis Vasileiadis
  • Georgios Boutzios
  • Georgios Charitoudis
  • Eleni Koukoulioti
  • Theodore Karatzas
Endocrine Tumors

Abstract

Background

Hashimoto thyroiditis (HT) is associated with an increased risk of developing papillary thyroid carcinoma (PTC). The relationship between thyroid autoimmunity and cancer remains controversial. The purpose of this study was to investigate whether the preoperative TgAb could be a potential predictor of PTC in patients with thyroid nodules and to assess whether there is an association of preoperative TgAb with lymph node metastases.

Methods

This retrospective, nonrandomised study included 854 patients who underwent standard total thyroidectomy. Benign thyroid nodules were diagnosed in 447 patients, and 407 presented with malignant nodules. The examined parameters included the clinical characteristics, preoperative TSH and TgAb levels, and the histopathological characteristics of the tumour.

Results

Tumour size >10 mm (p = 0.01), the presence of PTC (p < 0.001), elevated TSH levels (2.64 ± 1.28 μU/ml vs. 2.09 ± 0.98 μU/ml, p = 0.001), HT (p < 0.001), and lymph node metastasis (p = 0.005) were significantly associated with positive TgAb. Additionally, tumour size >10 mm (p < 0.001), preoperative TgAb positivity (p = 0.003), and elevated TSH levels (TSH > 3.4 μU/ml, p = 0.038) were independent risk factors for PTC based on the multivariate logistic regression analysis.

Conclusions

This study showed that TgAb positivity was an independent risk factor for PTC. A positive correlation between TgAb and PTC in patients with indeterminate nodules was existed. Additionally, a positive correlation existed between TgAb and lymph node metastases in patients with PTC. Prospective studies with a larger number of patients and long-term follow-up are needed clarify the potential role of positive serum TgAb in the prediction of PTC.

Keywords

Thyroid Carcinoma Papillary Thyroid Carcinoma Thyroid Nodule Autoimmune Thyroiditis Benign Nodule 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Conflict of interest

There are no potential conflicts of interest, financial or otherwise, for the participating authors.

References

  1. 1.
    Hegedüs L. Clinical practice: the thyroid nodule. N Engl J Med. 2004;351:1764–71.PubMedCrossRefGoogle Scholar
  2. 2.
    Marquesee E, Benson CB, Frates MC, Doubilet PM, Larsen PR, Cibas ES, Mandel SJ. Usefulness of ultrasonography in the management of nodular thyroid disease. Ann Intern Med. 2000;133:696–700.CrossRefGoogle Scholar
  3. 3.
    Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metabol. 2006;91:4295–301.CrossRefGoogle Scholar
  4. 4.
    Jonklaas J, Nsouli-Maktabi H, Soldin SJ. Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer. Thyroid. 2008;18:943–52.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Ito Y, Kudo T, Takamura Y, Kobayashi K, Miya A, Miyauchi A. Prognostic factors of papillary thyroid carcinoma vary according to sex and patient age. World J Surg. 2011;35:2684–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Frates MC, Benson CB, Doubilet PM, Kunreuther E, Contreras M, Cibas ES, Orcutt J, Moore FD Jr, Larsen PR, Marqusee E, Alexander EK. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 2006;91:3411–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS, Nicoloff JT. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1998;83:1121–7.PubMedGoogle Scholar
  8. 8.
    Xie LD, Gao Y, Li MR, Lu GZ, Guo XH. Distribution of immunoglobulin G subclasses of anti-thyroid peroxidase antibody in sera from patients with Hashimoto’s thyroiditis with different thyroid functional status. Clin Exp Immunol. 2008;154:172–6.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Silva LM, Chavez J, Canalli MH, Zanetti CR. Determination of IgG subclasses and avidity of antithyroid peroxidase antibodies in patients with subclinical hypothyroidism-a comparison with patients with overt hypothyroidism. Horm Res. 2003;59:118–24.PubMedCrossRefGoogle Scholar
  10. 10.
    McLachlan SM, Nagayama Y, Pichurin PN, Mizutori Y, Chen CR, Misharin A, Aliesky HA, Rapoport B. The link between Graves’ disease and Hashimoto’s thyroiditis: a role for regulatory T cells. Endocrinology. 2007;148:5724–33.PubMedCrossRefGoogle Scholar
  11. 11.
    Latrofa F, Ricci D, Grasso L, Vitti P, Masserini L, Basolo F, Ugolini C, Mascia G, Lucacchini A, Pinchera A. Characterization of thyroglobulin epitopes in patients with autoimmune and non-autoimmune thyroid diseases using recombinant human monoclonal thyroglobulin autoantibodies. J Clin Endocrinol Metab. 2008;93:591–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Boi F, Minerba L, Lai ML, Marziani B, Figus B, Spanu F, Borghero A, Mariotti S. Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules. J Endocrinol Invest. 2013;36:313–20.PubMedGoogle Scholar
  13. 13.
    Kim ES, Lim DJ, Baek KH, Lee JM, Kim MK, Kwon HS, Song KH, Kang MI, Cha BY, Lee KW, Son HY. Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules. Thyroid. 2010;20:885–91.PubMedCrossRefGoogle Scholar
  14. 14.
    Rago T, Di Coscio G, Ugolini C, Scutari M, Basolo F, Latrofa F, Romani R, Berti P, Grasso L, Braverman LE, Pinchera A, Vitti P. Clinical features of thyroid autoimmunity are associated with thyroiditis on histology and are not predictive of malignancy in 570 patients with indeterminate nodules on cytology who had a thyroidectomy. Clin Endocrinol. 2007;67:363–9.CrossRefGoogle Scholar
  15. 15.
    Holm LE, Blomgren H, Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. 1985;312:601–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H. Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res. 2008;150:49–52.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Konturek A, Barczynski M, Wierzchowski W, Stopa M, Nowak W. Coexistence of papillary thyroid cancer with Hashimoto thyroiditis. Langenbecks Arch Surg. 2013;398:389–94.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Boi F, Lai ML, Marziani B, Minerva L, Faa G, Mariotti S. High prevalence of suspicious cytology in thyroid nodules associated with positive thyroid autoantibodies. Eur J Endocrinol. 2005;153:637–42.PubMedCrossRefGoogle Scholar
  19. 19.
    Boutzios G, Vasileiadis I, Zapanti E, Charitoudis G, Karakostas E, Ieromonachou P, Karatzas T. Higher incidence of Tall cell variant of papillary thyroid carcinoma in Graves’ disease. Thyroid. 2014;24:347–54.Google Scholar
  20. 20.
    Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med. 1996;335:99–107.PubMedCrossRefGoogle Scholar
  21. 21.
    Okayasu I. The relationship of lymphatic thyroiditis to the development of thyroid carcinoma. Endocr Pathol. 1997;8:225–30.PubMedCrossRefGoogle Scholar
  22. 22.
    Singh B, Shaha AR, Trivedi H, Carew JF, Poluri A, Shah JP. Coexistent Hashimoto’s thyroiditis with papillary thyroid carcinoma: impact on presentation, management and outcome. Surgery. 1999;126:1070–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Latina A, Gullo D, Trimarchi F, Benvenga S. Hashimoto’s thyroiditis: similar and dissimilar characteristics in neighboring areas. Possible implications for the epidemiology of thyroid cancer. PLoS One. 2013;8(3):e55450.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metabol. 2008;93:809–14.CrossRefGoogle Scholar
  25. 25.
    Sinclair D. Clinical and laboratory aspects of thyroid autoantibodies. Ann Clin Biochem. 2006;43:173–83.PubMedCrossRefGoogle Scholar
  26. 26.
    Anil C, Goksel S, Gursov A. Hashimoto’s thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single institute prospective study. Thyroid. 2010;20:601–6.PubMedCrossRefGoogle Scholar
  27. 27.
    American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and differentiated thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American. Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.Google Scholar
  28. 28.
    Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705–15.PubMedCrossRefGoogle Scholar
  29. 29.
    McLeod DS, Cooper DS, Ladenson PW, Ain KB, Brierley J, Fein HG, Haugen BR, Jonklaas J, Magner J, Ross DD, Skarulis MC, Steward D, Maxon H, Sherman SI. Prognosis of differentiated thyroid cancer in relation to serum TSH and thyroglobulin antibody status at the time of diagnosis. Thyroid. 2014;24:35–42.Google Scholar
  30. 30.
    Fiore E, Rago T, Latrofa F, Provenzale MA, Piaggi P, Delitala A, Scutari M, Basolo F, Di Corsio G, Grasso L, Pinchera A, Vitti P. Hashimoto’s thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer. 2011;18:429–37.PubMedCrossRefGoogle Scholar
  31. 31.
    Fiore E, Rago T, Provenzale MA, Scutari M, Ugolini C, Basolo F, Di Corsio G, Berti P, Grasso L, Elisei R, Pinchera A, Vitti P. Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: thyroid autonomy may play a protective role. Endocr Relat Cancer. 2009;16:1251–60.PubMedCrossRefGoogle Scholar
  32. 32.
    Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008;144(6):980–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Vasileiadis I, Karakostas E, Charitoudis G, et al. Papillary thyroid microcarcinoma: clinicopathological characteristics and implications for treatment in 276 patients. Eur J Clin Invest. 2012;42:657–64.PubMedCrossRefGoogle Scholar
  34. 34.
    Giagourta I, Evangelopoulou C, Papaioannou G, Kassi G, Zapanti E, Prokopiou M, Papapostolou K, Karga H. Autoimmune thyroiditis in benign and malignant thyroid nodules: 16-year results. Head Neck. 2013. doi: 10.1002/hed.23331.

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Ioannis Vasileiadis
    • 1
  • Georgios Boutzios
    • 2
  • Georgios Charitoudis
    • 1
  • Eleni Koukoulioti
    • 2
  • Theodore Karatzas
    • 3
  1. 1.Department of Otolaryngology/Head and Neck SurgeryVenizeleio - Pananeio General Hospital, HerakleionAlexandroupolisGreece
  2. 2.Endocrine Unit, Department of Pathophysiology, Laikon General HospitalMedical School, University of AthensAthensGreece
  3. 3.Second Department of Propedeutic Surgery, Laikon General HospitalMedical School, University of AthensAthensGreece

Personalised recommendations